Allos Therapeutics to Present at Upcoming Investor Conferences
August 29 2006 - 8:30AM
PR Newswire (US)
WESTMINSTER, Colo., Aug. 29 /PRNewswire-FirstCall/ -- Allos
Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company's
management will participate in the following September investor
conferences: * Roth Capital Partners 2006 NY Conference --
management will provide a 30 minute corporate overview on
Wednesday, September 6 at 10:30 AM ET. * BioCentury's 13th Annual
NewsMakers in the Biotech Industry -- management will provide a 25
minute corporate overview on Thursday, September 7 at 10:30 AM ET.
* Bear Stearns 19th Annual Healthcare Conference -- management will
provide a 25 minute corporate overview on Monday, September 11 at
8:30 AM ET. Live and archived web casts of these presentations will
be available on the Company's website: http://www.allos.com/. About
Allos Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a
biopharmaceutical company focused on the development and
commercialization of small molecule therapeutics for the treatment
of cancer. The Company has two product candidates in late-stage
clinical development: EFAPROXYN (efaproxiral), a radiation
sensitizer currently under evaluation in a pivotal Phase 3 trial in
women with brain metastases originating from breast cancer, and PDX
(pralatrexate), a novel, next generation antifolate currently under
evaluation in a pivotal Phase 2 trial in patients with relapsed or
refractory peripheral T-cell lymphoma. The Company is also
evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1
trial in patients with advanced solid tumors. For additional
information, please visit the Company's website at
http://www.allos.com/ Safe Harbor Statement The anticipated
presentations will contain forward-looking statements that involve
significant risks and uncertainties, including those to be
discussed in the presentations and others that can be found in the
"Risk Factors" section of the Company's Form 10-K for the year
ended December 31, 2005 and in the Company's periodic reports on
Form 10-Q and Form 8-K. The Company does not undertake any
obligation to update any forward-looking statements contained in
the anticipated presentations as a result of new information,
future events or otherwise. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
the presentation. No forward-looking statement can be guaranteed
and actual events and results may differ materially from those
projected. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer
Neiman, Manager, Corporate Communications of Allos Therapeutics,
+1-720-540-5227, Web site: http://www.allos.com/
Copyright
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Oct 2023 to Oct 2024